The stakes are high for the all-day meeting on Sarepta's experimental gene therapy for Duchenne muscular dystrophy.May 12, 2023Check out STAT+Sponsored By Kristoffer Tripplaar/Sipa via AP STAT+ | Tracking the FDA advisory panel on Sarepta's gene therapy for Duchenne muscular dystrophy We'll be watching a livestream of the FDA advisory meeting on Sarepta's therapy and writing frequent updates and analysis throughout the day. By Adam Feuerstein and Jason Mast From fusion to retooling cancer trials, Eric Lander wants his new group to 'go after big problems' "I think it cuts to the heart of what scientists want to do, which is to go after big problems," Eric Lander told STAT. By Megan Molteni An ultrasound device may unlock brain cancer treatment, early study shows A new ultrasound device designed to deliver chemotherapy that crosses the blood-brain barrier shows promise. By Lizzy Lawrence Mike Reddy for STAT A physician's Mother's Day gift: reclaimed time with my children — and for myself I'm perpetually trying to resuscitate time. Just like CPR, attempts to resuscitate time are physically, mentally, and spiritually exhausting. By Jennifer Adaeze Okwerekwu Opinion: Proposed rules to protect health data in an era of abortion bans fall short In current form, the rules fail to help the people who need them most: those who live in states with abortion travel bans. By Eric D. Perakslis and Katie D. McMillan and Jessilyn Dunn More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Daily Recap? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments